Elena Ezhkova, PhD
- PROFESSOR | Cell, Developmental & Regenerative Biology
- PROFESSOR | Dermatology
Research Topics:Cancer, Cellular Differentiation, Developmental Biology, Epigenetics, Epithelial Cells, Stem Cells
Dr. Elena Ezhkova is a Professor of Cell, Developmental and Regenerative Biology and Dermatology. She is Director of Skin Biology and Diseases Resource-based Center (SBDRC) at Mount Sinai. She is a member of Black Family Stem Cell Institute and Tisch Cancer Center.
The long-term interest of Ezhkova lab is to elucidate molecular mechanisms that control epithelial stem cells during development and adulthood and to uncover how these processes are altered in human diseases, such as cancer.
For more information, please visit our website: https://www.ezhkova-lab.com/
Folow us on Twitter : https://twitter.com/EzhkovaLab
Multi-Disciplinary Training AreaDevelopment Regeneration and Stem Cells [DRS]
PhD, Cold Spring Harbor Laboratory
Postdoc, Rockefeller University
The Dr. Harold and Golden Lamport Research Award
Ellison Foundation New Scholar in Aging
Basil O’Connor Starter Award / March of Dimes
NIH K99/R00 Pathway to Independence Award (NIAMS)
New York Stem Cell Foundation Postdoctoral Fellow
Life Sciences Research Foundation Postdoctoral Fellow
Postdoc: Carolina Perdigoto (EMBO Postdoc Fellow), Julian Valdes (Pew Latin American Postdoc Fellow), Idan Cohen
PhD Student: Katherine Dauber (SDBBD T32 training grant), Carmit Bar (Merksammer Scholar)
PostDoc positions are available!
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Ezhkova did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.